To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Fig. 1 (A) Progression-free survival (PFS) and (B) overall survival (OS) for 464 patients treated with HD IL-2/IFN as first-line treatment for metastatic melanoma with a median follow-up time of 6.4 years. HD, high-dose; IFN; interferon; IL-2, interleukin-2. Fig.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Jon Kroll
Contact Jon Kroll, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack